 | • レポートコード：MRC2Q12-00045 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：農業 |
| Single User | ￥686,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,372,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、不活性化豚萎縮性鼻炎ワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 不活性化豚萎縮性鼻炎ワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 不活性化豚萎縮性鼻炎ワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 不活性化豚萎縮性鼻炎ワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの不活性化豚萎縮性鼻炎ワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の不活性化豚萎縮性鼻炎ワクチンの売上および2028年までの予測に焦点を当てています。 不活性化豚萎縮性鼻炎ワクチンのグローバル主要企業には、Merck Animal Health、HIPRA、Bioveta、China Animal Husbandy Industry、Wuhan Keqian Biology、Pulike Bio-Engineering、Tiankang Animal Science Bio-Technology、Tianjin Ringpu Bio-Technologyなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 不活性化豚萎縮性鼻炎ワクチン市場は、タイプとアプリケーションによって区分されます。世界の不活性化豚萎縮性鼻炎ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 組織培養由来、細胞株由来 【アプリケーション別セグメント】 雌豚、雌子豚 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 不活性化豚萎縮性鼻炎ワクチン製品概要 - タイプ別市場（組織培養由来、細胞株由来） - アプリケーション別市場（雌豚、雌子豚） - 調査の目的 ・エグゼクティブサマリー - 世界の不活性化豚萎縮性鼻炎ワクチン販売量予測2017-2028 - 世界の不活性化豚萎縮性鼻炎ワクチン売上予測2017-2028 - 不活性化豚萎縮性鼻炎ワクチンの地域別販売量 - 不活性化豚萎縮性鼻炎ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別不活性化豚萎縮性鼻炎ワクチン販売量 - 主要メーカー別不活性化豚萎縮性鼻炎ワクチン売上 - 主要メーカー別不活性化豚萎縮性鼻炎ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（組織培養由来、細胞株由来） - 不活性化豚萎縮性鼻炎ワクチンのタイプ別販売量 - 不活性化豚萎縮性鼻炎ワクチンのタイプ別売上 - 不活性化豚萎縮性鼻炎ワクチンのタイプ別価格 ・アプリケーション別市場規模（雌豚、雌子豚） - 不活性化豚萎縮性鼻炎ワクチンのアプリケーション別販売量 - 不活性化豚萎縮性鼻炎ワクチンのアプリケーション別売上 - 不活性化豚萎縮性鼻炎ワクチンのアプリケーション別価格 ・北米市場 - 北米の不活性化豚萎縮性鼻炎ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚萎縮性鼻炎ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの不活性化豚萎縮性鼻炎ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚萎縮性鼻炎ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の不活性化豚萎縮性鼻炎ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚萎縮性鼻炎ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の不活性化豚萎縮性鼻炎ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚萎縮性鼻炎ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの不活性化豚萎縮性鼻炎ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚萎縮性鼻炎ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 Merck Animal Health、HIPRA、Bioveta、China Animal Husbandy Industry、Wuhan Keqian Biology、Pulike Bio-Engineering、Tiankang Animal Science Bio-Technology、Tianjin Ringpu Bio-Technology ・産業チェーン及び販売チャネル分析 - 不活性化豚萎縮性鼻炎ワクチンの産業チェーン分析 - 不活性化豚萎縮性鼻炎ワクチンの原材料 - 不活性化豚萎縮性鼻炎ワクチンの生産プロセス - 不活性化豚萎縮性鼻炎ワクチンの販売及びマーケティング - 不活性化豚萎縮性鼻炎ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 不活性化豚萎縮性鼻炎ワクチンの産業動向 - 不活性化豚萎縮性鼻炎ワクチンのマーケットドライバー - 不活性化豚萎縮性鼻炎ワクチンの課題 - 不活性化豚萎縮性鼻炎ワクチンの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Inactivated Porcine Atrophic Rhinitis Vaccine estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Inactivated Porcine Atrophic Rhinitis Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Inactivated Porcine Atrophic Rhinitis Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Inactivated Porcine Atrophic Rhinitis Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Inactivated Porcine Atrophic Rhinitis Vaccine include Merck Animal Health, HIPRA, Bioveta, China Animal Husbandy Industry, Wuhan Keqian Biology, Pulike Bio-Engineering, Tiankang Animal Science Bio-Technology and Tianjin Ringpu Bio-Technology, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Inactivated Porcine Atrophic Rhinitis Vaccine companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Inactivated Porcine Atrophic Rhinitis Vaccine market. Further, it explains the major drivers and regional dynamics of the global Inactivated Porcine Atrophic Rhinitis Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Merck Animal Health
HIPRA
Bioveta
China Animal Husbandy Industry
Wuhan Keqian Biology
Pulike Bio-Engineering
Tiankang Animal Science Bio-Technology
Tianjin Ringpu Bio-Technology
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Inactivated Porcine Atrophic Rhinitis Vaccine Segment by Type
Tissue Culture Origin
Cell Line Origin
Inactivated Porcine Atrophic Rhinitis Vaccine Segment by Application
Sows
Gilts
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Inactivated Porcine Atrophic Rhinitis Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Inactivated Porcine Atrophic Rhinitis Vaccine market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Inactivated Porcine Atrophic Rhinitis Vaccine, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Inactivated Porcine Atrophic Rhinitis Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Inactivated Porcine Atrophic Rhinitis Vaccine revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Inactivated Porcine Atrophic Rhinitis Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Inactivated Porcine Atrophic Rhinitis Vaccine revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck Animal Health, HIPRA, Bioveta, China Animal Husbandy Industry, Wuhan Keqian Biology, Pulike Bio-Engineering, Tiankang Animal Science Bio-Technology and Tianjin Ringpu Bio-Technology, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Inactivated Porcine Atrophic Rhinitis Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Inactivated Porcine Atrophic Rhinitis Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inactivated Porcine Atrophic Rhinitis Vaccine revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Inactivated Porcine Atrophic Rhinitis Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Tissue Culture Origin
1.2.3 Cell Line Origin
1.3 Market by Application
1.3.1 Global Inactivated Porcine Atrophic Rhinitis Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Sows
1.3.3 Gilts
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Inactivated Porcine Atrophic Rhinitis Vaccine Market Perspective (2017-2028)
2.2 Inactivated Porcine Atrophic Rhinitis Vaccine Growth Trends by Region
2.2.1 Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Inactivated Porcine Atrophic Rhinitis Vaccine Historic Market Size by Region (2017-2022)
2.2.3 Inactivated Porcine Atrophic Rhinitis Vaccine Forecasted Market Size by Region (2023-2028)
2.3 Inactivated Porcine Atrophic Rhinitis Vaccine Market Dynamics
2.3.1 Inactivated Porcine Atrophic Rhinitis Vaccine Industry Trends
2.3.2 Inactivated Porcine Atrophic Rhinitis Vaccine Market Drivers
2.3.3 Inactivated Porcine Atrophic Rhinitis Vaccine Market Challenges
2.3.4 Inactivated Porcine Atrophic Rhinitis Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Inactivated Porcine Atrophic Rhinitis Vaccine Players by Revenue
3.1.1 Global Top Inactivated Porcine Atrophic Rhinitis Vaccine Players by Revenue (2017-2022)
3.1.2 Global Inactivated Porcine Atrophic Rhinitis Vaccine Revenue Market Share by Players (2017-2022)
3.2 Global Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Inactivated Porcine Atrophic Rhinitis Vaccine Revenue
3.4 Global Inactivated Porcine Atrophic Rhinitis Vaccine Market Concentration Ratio
3.4.1 Global Inactivated Porcine Atrophic Rhinitis Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Inactivated Porcine Atrophic Rhinitis Vaccine Revenue in 2021
3.5 Inactivated Porcine Atrophic Rhinitis Vaccine Key Players Head office and Area Served
3.6 Key Players Inactivated Porcine Atrophic Rhinitis Vaccine Product Solution and Service
3.7 Date of Enter into Inactivated Porcine Atrophic Rhinitis Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Inactivated Porcine Atrophic Rhinitis Vaccine Breakdown Data by Type
4.1 Global Inactivated Porcine Atrophic Rhinitis Vaccine Historic Market Size by Type (2017-2022)
4.2 Global Inactivated Porcine Atrophic Rhinitis Vaccine Forecasted Market Size by Type (2023-2028)
5 Inactivated Porcine Atrophic Rhinitis Vaccine Breakdown Data by Application
5.1 Global Inactivated Porcine Atrophic Rhinitis Vaccine Historic Market Size by Application (2017-2022)
5.2 Global Inactivated Porcine Atrophic Rhinitis Vaccine Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size (2017-2028)
6.2 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type
6.2.1 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2017-2022)
6.2.2 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2023-2028)
6.2.3 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Type (2017-2028)
6.3 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application
6.3.1 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2017-2022)
6.3.2 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2023-2028)
6.3.3 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Application (2017-2028)
6.4 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country
6.4.1 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country (2017-2022)
6.4.2 North America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size (2017-2028)
7.2 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type
7.2.1 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2017-2022)
7.2.2 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2023-2028)
7.2.3 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Type (2017-2028)
7.3 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application
7.3.1 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2017-2022)
7.3.2 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2023-2028)
7.3.3 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Application (2017-2028)
7.4 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country
7.4.1 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country (2017-2022)
7.4.2 Europe Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size (2017-2028)
8.2 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type
8.2.1 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Type (2017-2028)
8.3 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application
8.3.1 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Application (2017-2028)
8.4 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Region
8.4.1 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size (2017-2028)
9.2 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type
9.2.1 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2017-2022)
9.2.2 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2023-2028)
9.2.3 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Type (2017-2028)
9.3 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application
9.3.1 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2017-2022)
9.3.2 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2023-2028)
9.3.3 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Application (2017-2028)
9.4 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country
9.4.1 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country (2017-2022)
9.4.2 Latin America Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size (2017-2028)
10.2 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type
10.2.1 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Type (2017-2028)
10.3 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application
10.3.1 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Share by Application (2017-2028)
10.4 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country
10.4.1 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Inactivated Porcine Atrophic Rhinitis Vaccine Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Merck Animal Health
11.1.1 Merck Animal Health Company Details
11.1.2 Merck Animal Health Business Overview
11.1.3 Merck Animal Health Inactivated Porcine Atrophic Rhinitis Vaccine Introduction
11.1.4 Merck Animal Health Revenue in Inactivated Porcine Atrophic Rhinitis Vaccine Business (2017-2022)
11.1.5 Merck Animal Health Recent Developments
11.2 HIPRA
11.2.1 HIPRA Company Details
11.2.2 HIPRA Business Overview
11.2.3 HIPRA Inactivated Porcine Atrophic Rhinitis Vaccine Introduction
11.2.4 HIPRA Revenue in Inactivated Porcine Atrophic Rhinitis Vaccine Business (2017-2022)
11.2.5 HIPRA Recent Developments
11.3 Bioveta
11.3.1 Bioveta Company Details
11.3.2 Bioveta Business Overview
11.3.3 Bioveta Inactivated Porcine Atrophic Rhinitis Vaccine Introduction
11.3.4 Bioveta Revenue in Inactivated Porcine Atrophic Rhinitis Vaccine Business (2017-2022)
11.3.5 Bioveta Recent Developments
11.4 China Animal Husbandy Industry
11.4.1 China Animal Husbandy Industry Company Details
11.4.2 China Animal Husbandy Industry Business Overview
11.4.3 China Animal Husbandy Industry Inactivated Porcine Atrophic Rhinitis Vaccine Introduction
11.4.4 China Animal Husbandy Industry Revenue in Inactivated Porcine Atrophic Rhinitis Vaccine Business (2017-2022)
11.4.5 China Animal Husbandy Industry Recent Developments
11.5 Wuhan Keqian Biology
11.5.1 Wuhan Keqian Biology Company Details
11.5.2 Wuhan Keqian Biology Business Overview
11.5.3 Wuhan Keqian Biology Inactivated Porcine Atrophic Rhinitis Vaccine Introduction
11.5.4 Wuhan Keqian Biology Revenue in Inactivated Porcine Atrophic Rhinitis Vaccine Business (2017-2022)
11.5.5 Wuhan Keqian Biology Recent Developments
11.6 Pulike Bio-Engineering
11.6.1 Pulike Bio-Engineering Company Details
11.6.2 Pulike Bio-Engineering Business Overview
11.6.3 Pulike Bio-Engineering Inactivated Porcine Atrophic Rhinitis Vaccine Introduction
11.6.4 Pulike Bio-Engineering Revenue in Inactivated Porcine Atrophic Rhinitis Vaccine Business (2017-2022)
11.6.5 Pulike Bio-Engineering Recent Developments
11.7 Tiankang Animal Science Bio-Technology
11.7.1 Tiankang Animal Science Bio-Technology Company Details
11.7.2 Tiankang Animal Science Bio-Technology Business Overview
11.7.3 Tiankang Animal Science Bio-Technology Inactivated Porcine Atrophic Rhinitis Vaccine Introduction
11.7.4 Tiankang Animal Science Bio-Technology Revenue in Inactivated Porcine Atrophic Rhinitis Vaccine Business (2017-2022)
11.7.5 Tiankang Animal Science Bio-Technology Recent Developments
11.8 Tianjin Ringpu Bio-Technology
11.8.1 Tianjin Ringpu Bio-Technology Company Details
11.8.2 Tianjin Ringpu Bio-Technology Business Overview
11.8.3 Tianjin Ringpu Bio-Technology Inactivated Porcine Atrophic Rhinitis Vaccine Introduction
11.8.4 Tianjin Ringpu Bio-Technology Revenue in Inactivated Porcine Atrophic Rhinitis Vaccine Business (2017-2022)
11.8.5 Tianjin Ringpu Bio-Technology Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer